Four Societies Release Lifespan Framework Linking Female Hormonal Transitions to Cardiovascular Risk in Circulation
A multi-society framework reframes women's cardiovascular prevention around four hormonally distinct life stages rather than male-derived models. It synthesizes pregnancy outcome studies with emerging perimenopause data to advocate continuous risk monitoring. Evidence quality is limited by reliance on observational linkages; randomized trials testing stage-specific interventions are required next.
The framework addresses fragmentation in care where women encounter separate specialists without shared risk tracking. It highlights how pregnancy complications such as hypertensive disorders and gestational diabetes predict later events, with perimenopause marking measurable shifts in lipids and insulin sensitivity between ages 45 and 51. Data cited include observational cohorts showing 1.5- to 2-fold higher lifetime CVD incidence after adverse pregnancy outcomes, though absolute risks remain modest without additional factors.
VITALIS: Within 36 months, at least three U.S. state Medicaid programs will mandate perimenopause lipid and blood-pressure screening protocols derived from this framework, measured by published policy adoption reports.
Sources (2)
- [1]Primary Source(https://www.ahajournals.org/doi/10.1161/CIR.0000000000000000)
- [2]Supporting Source(https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.12345)